Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Friday, July 10, 2026
In today's episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Eva Johnson cover the retraction of the Advocate trial after FDA reviewers found the avacopan (Tavneos) dataset was unblinded, re-adjudicated, and altered before being relocked, throwing its approval for ANCA-associated vasculitis into doubt. They break down Medicare's new GLP-1 Bridge program, which offers eligible Part D beneficiaries drugs like Wegovy and Zepbound at $50 a month through the end of 2027, and why that copay sits outside normal Part D accounting. They also track a Cyclospora outbreak now reported across 18 states and why routine washing does not reliably kill it. Plus: they also discuss Alibaba's $600 million fentanyl-precursor settlement, the WHO's first emergency-use Ebola (Bundibugyo) diagnostic, France's deadly heat wave, and more.
Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com.
Sources & Media Attributions for Today's Episode Available At:
